1213 related articles for article (PubMed ID: 19531622)
1. Vaccination with recombinant NY-ESO-1 protein elicits immunodominant HLA-DR52b-restricted CD4+ T cell responses with a conserved T cell receptor repertoire.
Bioley G; Dousset C; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Ayyoub M; Valmori D
Clin Cancer Res; 2009 Jul; 15(13):4467-74. PubMed ID: 19531622
[TBL] [Abstract][Full Text] [Related]
2. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
[TBL] [Abstract][Full Text] [Related]
3. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells.
Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM
Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380
[TBL] [Abstract][Full Text] [Related]
4. HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.
Bioley G; Guillaume P; Luescher I; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Valmori D; Ayyoub M
Clin Cancer Res; 2009 Jan; 15(1):299-306. PubMed ID: 19118058
[TBL] [Abstract][Full Text] [Related]
5. A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design.
Ebert LM; Liu YC; Clements CS; Robson NC; Jackson HM; Markby JL; Dimopoulos N; Tan BS; Luescher IF; Davis ID; Rossjohn J; Cebon J; Purcell AW; Chen W
Cancer Res; 2009 Feb; 69(3):1046-54. PubMed ID: 19176376
[TBL] [Abstract][Full Text] [Related]
6. NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.
Zarour HM; Storkus WJ; Brusic V; Williams E; Kirkwood JM
Cancer Res; 2000 Sep; 60(17):4946-52. PubMed ID: 10987311
[TBL] [Abstract][Full Text] [Related]
7. A phenotype based approach for the immune monitoring of NY-ESO-1-specific CD4+ T cell responses in cancer patients.
Ayyoub M; Souleimanian NE; Godefroy E; Scotto L; Hesdorffer CS; Old LJ; Valmori D
Clin Immunol; 2006; 118(2-3):188-94. PubMed ID: 16368270
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.
Odunsi K; Qian F; Matsuzaki J; Mhawech-Fauceglia P; Andrews C; Hoffman EW; Pan L; Ritter G; Villella J; Thomas B; Rodabaugh K; Lele S; Shrikant P; Old LJ; Gnjatic S
Proc Natl Acad Sci U S A; 2007 Jul; 104(31):12837-42. PubMed ID: 17652518
[TBL] [Abstract][Full Text] [Related]
9. Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo.
Garcia Casado J; Janda J; Wei J; Chapatte L; Colombetti S; Alves P; Ritter G; Ayyoub M; Valmori D; Chen W; Lévy F
Eur J Immunol; 2008 Jul; 38(7):1867-76. PubMed ID: 18546142
[TBL] [Abstract][Full Text] [Related]
10. In vitro stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: Identification of a new HLA-DR15-binding CD4 T-cell epitope.
Hasegawa K; Noguchi Y; Koizumi F; Uenaka A; Tanaka M; Shimono M; Nakamura H; Shiku H; Gnjatic S; Murphy R; Hiramatsu Y; Old LJ; Nakayama E
Clin Cancer Res; 2006 Mar; 12(6):1921-7. PubMed ID: 16551878
[TBL] [Abstract][Full Text] [Related]
11. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.
Held G; Matsuo M; Epel M; Gnjatic S; Ritter G; Lee SY; Tai TY; Cohen CJ; Old LJ; Pfreundschuh M; Reiter Y; Hoogenboom HR; Renner C
Eur J Immunol; 2004 Oct; 34(10):2919-29. PubMed ID: 15368308
[TBL] [Abstract][Full Text] [Related]
12. Immune responses detected in urothelial carcinoma patients after vaccination with NY-ESO-1 protein plus BCG and GM-CSF.
Sharma P; Bajorin DF; Jungbluth AA; Herr H; Old LJ; Gnjatic S
J Immunother; 2008; 31(9):849-57. PubMed ID: 18833002
[TBL] [Abstract][Full Text] [Related]
13. Assessment of vaccine-induced CD4 T cell responses to the 119-143 immunodominant region of the tumor-specific antigen NY-ESO-1 using DRB1*0101 tetramers.
Ayyoub M; Pignon P; Dojcinovic D; Raimbaud I; Old LJ; Luescher I; Valmori D
Clin Cancer Res; 2010 Sep; 16(18):4607-15. PubMed ID: 20670945
[TBL] [Abstract][Full Text] [Related]
14. Quantitative and qualitative assessment of circulating NY-ESO-1 specific CD4+ T cells in cancer-free individuals.
Valmori D; Souleimanian NE; Hesdorffer CS; Old LJ; Ayyoub M
Clin Immunol; 2005 Nov; 117(2):161-7. PubMed ID: 16103015
[TBL] [Abstract][Full Text] [Related]
15. Three novel NY-ESO-1 epitopes bound to DRB1*0803, DQB1*0401 and DRB1*0901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients.
Mizote Y; Taniguchi T; Tanaka K; Isobe M; Wada H; Saika T; Kita S; Koide Y; Uenaka A; Nakayama E
Vaccine; 2010 Jul; 28(32):5338-46. PubMed ID: 20665979
[TBL] [Abstract][Full Text] [Related]
16. One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.
Mandic M; Castelli F; Janjic B; Almunia C; Andrade P; Gillet D; Brusic V; Kirkwood JM; Maillere B; Zarour HM
J Immunol; 2005 Feb; 174(3):1751-9. PubMed ID: 15661941
[TBL] [Abstract][Full Text] [Related]
17. Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient.
Tsuji K; Hamada T; Uenaka A; Wada H; Sato E; Isobe M; Asagoe K; Yamasaki O; Shiku H; Ritter G; Murphy R; Hoffman EW; Old LJ; Nakayama E; Iwatsuki K
Cancer Immunol Immunother; 2008 Oct; 57(10):1429-37. PubMed ID: 18311489
[TBL] [Abstract][Full Text] [Related]
18. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen.
Rodolfo M; Luksch R; Stockert E; Chen YT; Collini P; Ranzani T; Lombardo C; Dalerba P; Rivoltini L; Arienti F; Fossati-Bellani F; Old LJ; Parmiani G; Castelli C
Cancer Res; 2003 Oct; 63(20):6948-55. PubMed ID: 14583496
[TBL] [Abstract][Full Text] [Related]
19. The alternative open reading frame of LAGE-1 gives rise to multiple promiscuous HLA-DR-restricted epitopes recognized by T-helper 1-type tumor-reactive CD4+ T cells.
Mandic M; Almunia C; Vicel S; Gillet D; Janjic B; Coval K; Maillere B; Kirkwood JM; Zarour HM
Cancer Res; 2003 Oct; 63(19):6506-15. PubMed ID: 14559844
[TBL] [Abstract][Full Text] [Related]
20. Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1.
Matsuzaki J; Qian F; Luescher I; Lele S; Ritter G; Shrikant PA; Gnjatic S; Old LJ; Odunsi K
Cancer Immunol Immunother; 2008 Aug; 57(8):1185-95. PubMed ID: 18253733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
